CN116601713A - 用于抗her2抗体-药物缀合物疗法的评分方法 - Google Patents

用于抗her2抗体-药物缀合物疗法的评分方法 Download PDF

Info

Publication number
CN116601713A
CN116601713A CN202180077294.6A CN202180077294A CN116601713A CN 116601713 A CN116601713 A CN 116601713A CN 202180077294 A CN202180077294 A CN 202180077294A CN 116601713 A CN116601713 A CN 116601713A
Authority
CN
China
Prior art keywords
cancer
adc
cell
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180077294.6A
Other languages
English (en)
Chinese (zh)
Inventor
G·施密特
N·布里厄
A·斯皮茨穆勒
A·卡皮尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Daiichi Sankyo Co Ltd
Original Assignee
AstraZeneca UK Ltd
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd, Daiichi Sankyo Co Ltd filed Critical AstraZeneca UK Ltd
Publication of CN116601713A publication Critical patent/CN116601713A/zh
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G06COMPUTING OR CALCULATING; COUNTING
    • G06VIMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V20/00Scenes; Scene-specific elements
    • G06V20/60Type of objects
    • G06V20/69Microscopic objects, e.g. biological cells or cellular parts
    • G06V20/698Matching; Classification
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • GPHYSICS
    • G06COMPUTING OR CALCULATING; COUNTING
    • G06FELECTRIC DIGITAL DATA PROCESSING
    • G06F18/00Pattern recognition
    • G06F18/20Analysing
    • G06F18/24Classification techniques
    • G06F18/241Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches
    • G06F18/2413Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches based on distances to training or reference patterns
    • G06F18/24133Distances to prototypes
    • GPHYSICS
    • G06COMPUTING OR CALCULATING; COUNTING
    • G06VIMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V10/00Arrangements for image or video recognition or understanding
    • G06V10/40Extraction of image or video features
    • G06V10/44Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersections; Connectivity analysis, e.g. of connected components
    • G06V10/443Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersections; Connectivity analysis, e.g. of connected components by matching or filtering
    • G06V10/449Biologically inspired filters, e.g. difference of Gaussians [DoG] or Gabor filters
    • G06V10/451Biologically inspired filters, e.g. difference of Gaussians [DoG] or Gabor filters with interaction between the filter responses, e.g. cortical complex cells
    • G06V10/454Integrating the filters into a hierarchical structure, e.g. convolutional neural networks [CNN]
    • GPHYSICS
    • G06COMPUTING OR CALCULATING; COUNTING
    • G06VIMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V10/00Arrangements for image or video recognition or understanding
    • G06V10/70Arrangements for image or video recognition or understanding using pattern recognition or machine learning
    • G06V10/74Image or video pattern matching; Proximity measures in feature spaces
    • G06V10/75Organisation of the matching processes, e.g. simultaneous or sequential comparisons of image or video features; Coarse-fine approaches, e.g. multi-scale approaches; using context analysis; Selection of dictionaries
    • G06V10/751Comparing pixel values or logical combinations thereof, or feature values having positional relevance, e.g. template matching
    • GPHYSICS
    • G06COMPUTING OR CALCULATING; COUNTING
    • G06VIMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V20/00Scenes; Scene-specific elements
    • G06V20/60Type of objects
    • G06V20/69Microscopic objects, e.g. biological cells or cellular parts
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G06COMPUTING OR CALCULATING; COUNTING
    • G06VIMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V2201/00Indexing scheme relating to image or video recognition or understanding
    • G06V2201/03Recognition of patterns in medical or anatomical images

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Multimedia (AREA)
  • Evolutionary Computation (AREA)
  • Artificial Intelligence (AREA)
  • Medicinal Chemistry (AREA)
  • Data Mining & Analysis (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Software Systems (AREA)
  • Medical Informatics (AREA)
  • Databases & Information Systems (AREA)
  • Computing Systems (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
CN202180077294.6A 2020-09-12 2021-09-11 用于抗her2抗体-药物缀合物疗法的评分方法 Pending CN116601713A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063077604P 2020-09-12 2020-09-12
US63/077604 2020-09-12
PCT/IB2021/058273 WO2022054009A2 (en) 2020-09-12 2021-09-11 A scoring method for an anti-her2 antibody-drug conjugate therapy

Publications (1)

Publication Number Publication Date
CN116601713A true CN116601713A (zh) 2023-08-15

Family

ID=77801755

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180077294.6A Pending CN116601713A (zh) 2020-09-12 2021-09-11 用于抗her2抗体-药物缀合物疗法的评分方法

Country Status (10)

Country Link
US (1) US20240426826A1 (https=)
EP (1) EP4211598B1 (https=)
JP (1) JP2023545359A (https=)
KR (1) KR20230066094A (https=)
CN (1) CN116601713A (https=)
AU (2) AU2021340002B9 (https=)
CA (1) CA3195062A1 (https=)
ES (1) ES3064041T3 (https=)
IL (1) IL301265A (https=)
WO (1) WO2022054009A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025103192A1 (zh) * 2023-11-16 2025-05-22 上海齐鲁制药研究中心有限公司 一种氘代喜树碱化合物及其制备和应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240037740A1 (en) * 2022-07-28 2024-02-01 Applied Materials, Inc. Method and system for automatic ihc marker-her2 score
EP4623936A1 (en) * 2022-11-22 2025-10-01 Keymed Biosciences (Chengdu) Co., Ltd. Fused ring compound, conjugate thereof and use thereof
WO2025162211A1 (zh) * 2024-01-29 2025-08-07 正大天晴药业集团股份有限公司 抗her2抗体药物偶联物治疗胃癌的用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107743586A (zh) * 2015-06-03 2018-02-27 百时美施贵宝公司 用于癌症诊断的抗gitr抗体
US20190026422A1 (en) * 2015-02-16 2019-01-24 Lonza Ltd Method and apparatus for designing proteins
US20190392580A1 (en) * 2018-06-26 2019-12-26 Definiens Ag Deep Learning Method For Tumor Cell Scoring On Cancer Biopsies
CN110651188A (zh) * 2017-03-03 2020-01-03 特雷斯生物公司 基于群体的免疫原性肽鉴定平台
WO2020023213A1 (en) * 2018-07-27 2020-01-30 Ventana Medical Systems, Inc. Systems for automated in situ hybridization analysis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
EP2854851A4 (en) * 2012-06-01 2016-03-30 Momenta Pharmaceuticals Inc Methods related to trastuzumab
IL310627B2 (en) * 2014-01-31 2026-04-01 Daiichi Sankyo Co Ltd Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof
EP3659110A1 (en) * 2017-07-24 2020-06-03 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in tumor samples
EP3721373B1 (en) * 2017-12-07 2025-03-05 Ventana Medical Systems, Inc. Deep-learning systems and methods for joint cell and region classification in biological images
EP3797296B1 (en) * 2018-05-21 2024-09-04 Genentech, Inc. Her2 heterogeneity as a biomarker in cancer
WO2022162164A1 (en) * 2021-01-29 2022-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190026422A1 (en) * 2015-02-16 2019-01-24 Lonza Ltd Method and apparatus for designing proteins
CN107743586A (zh) * 2015-06-03 2018-02-27 百时美施贵宝公司 用于癌症诊断的抗gitr抗体
CN110651188A (zh) * 2017-03-03 2020-01-03 特雷斯生物公司 基于群体的免疫原性肽鉴定平台
US20190392580A1 (en) * 2018-06-26 2019-12-26 Definiens Ag Deep Learning Method For Tumor Cell Scoring On Cancer Biopsies
WO2020023213A1 (en) * 2018-07-27 2020-01-30 Ventana Medical Systems, Inc. Systems for automated in situ hybridization analysis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025103192A1 (zh) * 2023-11-16 2025-05-22 上海齐鲁制药研究中心有限公司 一种氘代喜树碱化合物及其制备和应用

Also Published As

Publication number Publication date
IL301265A (en) 2023-05-01
JP2023545359A (ja) 2023-10-30
AU2021340002B2 (en) 2024-06-20
EP4211598B1 (en) 2026-01-07
CA3195062A1 (en) 2022-03-17
AU2021340002A1 (en) 2023-05-25
US20240426826A1 (en) 2024-12-26
WO2022054009A2 (en) 2022-03-17
ES3064041T3 (en) 2026-04-22
EP4211598A2 (en) 2023-07-19
AU2024219803A1 (en) 2024-10-10
WO2022054009A3 (en) 2022-04-21
KR20230066094A (ko) 2023-05-12
AU2021340002B9 (en) 2024-09-12
AU2021340002A9 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
AU2021340002B2 (en) A scoring method for an anti-her2 antibody-drug conjugate therapy
JP4799863B2 (ja) 癌制御方法
US20230176060A1 (en) Tumour biomarkers for immunotherapy
JP2025509564A (ja) 抗trop2抗体-薬物コンジュゲート治療のためのスコアリング方法
RU2706967C2 (ru) Антитело к igf-1r и его применение для диагностики рака
JP7829563B2 (ja) 抗b7h4抗体薬物コンジュゲート療法のためのスコア化方法
RU2706959C2 (ru) Антитело к igf-1r и его применение для диагностики рака
JP2023542301A5 (https=)
WO2026052764A1 (en) A scoring method for an anti-trop2 antibody drug conjugate therapy
US20250352645A1 (en) Biomarkers and methods for treating nsclc
US11046779B2 (en) Antibody specifically binding to PAUF protein and use thereof
HK40025609A (en) Antibody specifically binding to pauf protein and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination